Benzinga | Aug 9, 2021 04:09PM EDT

Cara Therapeutics Q2 EPS $(0.61) Misses $(0.53) Estimate

Cara Therapeutics (NASDAQ:CARA) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.53) by 15.09 percent. This is a 12.96 percent decrease over losses of $(0.54) per share from the same period last year.